Ausgabe 4/2013
Inhalt (33 Artikel)
Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model
Ya-Jen Chang, Chin-Wei Hsu, Chih-Hsien Chang, Keng-Li Lan, Gann Ting, Te-Wei Lee
Functional and molecular characterization of kinin B1 and B2 receptors in human bladder cancer: implication of the PI3Kγ pathway
V. Sgnaolin, T. C. B. Pereira, M. R. Bogo, R. Zanin, A. M. O. Battastini, F. B. Morrone, M. M. Campos
Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons
Frank Leigh Lu, Ching-Chia Yu, Huei-Hsuan Chiu, Hsingjin Eugene Liu, Shao-Yin Chen, Shufan Lin, Ting-Yi Goh, Hsin-Chih Hsu, Chih-Han Chien, Han-Chung Wu, Ming-Shan Chen, Scott C. Schuyler, Wu-Shiun Hsieh, Mei-Hwan Wu, Jean Lu
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan, Victoria L. Peek, Rose Ajamie, Sean G. Buchanan, Jeremy R. Graff, Steven A. Heidler, Yu-Hua Hui, Karen L. Huss, Bruce W. Konicek, Jason R. Manro, Chuan Shih, Julie A. Stewart, Trent R. Stewart, Stephanie L. Stout, Mark T. Uhlik, Suzane L. Um, Yong Wang, Wenjuan Wu, Lei Yan, Wei J. Yang, Boyu Zhong, Richard A. Walgren
Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer
Peter M. Wilson, Melissa J. LaBonte, Shelby C. Martin, Stephanie T. Kuwahara, Anthony El-Khoueiry, Heinz-Josef Lenz, Robert D. Ladner
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells
Angel Mauricio Castro-Gamero, Kleiton Silva Borges, Daniel Antunes Moreno, Veridiana Kill Suazo, Mayara Missono Fujinami, Rosane de Paula Gomes Queiroz, Harley Francisco de Oliveira, Carlos Gilberto Carlotti Jr., Carlos Alberto Scrideli, Luiz Gonzaga Tone
Preclinical antitumor activity of a nanoparticulate SN38
Mazin F. Al-kasspooles, Stephen K. Williamson, David Henry, Jahna Howell, Fengui Niu, Charles J. Decedue, Katherine F. Roby
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach
L. Heijmen, C. J. A. Punt, E. G. W. ter Voert, L. F. de Geus-Oei, A. Heerschap, J. Bussink, C. G. J. Sweep, V. Zerbi, W. J. G. Oyen, P. N. Span, O. Boerman, H. W. M. van Laarhoven
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib
Grace K. Dy, Jeffrey R. Infante, S. Gail Eckhardt, Silvia Novello, Wen Wee Ma, Suzanne F. Jones, Anne Huff, Qiong Wang, A. Benjamin Suttle, Lone H. Ottesen, Alex A. Adjei, Howard A. Burris III
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors
Thierry Lesimple, Julien Edeline, Timothy J. Carrothers, Frédérique Cvitkovic, Borje Darpo, Jean-Pierre Delord, Hervé Léna, Nicolas Penel, Geoff J. Edwards, Kenneth Law, Jantien Wanders, Allan Kristensen, Larisa Reyderman
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
Takayuki Yoshino, Kentaro Yamazaki, Kensei Yamaguchi, Toshihiko Doi, Narikazu Boku, Nozomu Machida, Yusuke Onozawa, Masako Asayama, Tadahiro Fujino, Atsushi Ohtsu
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
David S. Hong, Jennifer Hsing Choe, Aung Naing, Jennifer J. Wheler, Gerald S. Falchook, Sarina Piha-Paul, Stacy L. Moulder, Goldy C. George, Jonathan M. Choe, Lewis C. Strauss, Gary E. Gallick, Razelle Kurzrock
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors
Jeffrey R. Infante, Silvia Novello, Wen Wee Ma, Grace K. Dy, Johanna C. Bendell, Anne Huff, Qiong Wang, A. Benjamin Suttle, Robert Allen, Chun-Fang Xu, Lone H. Ottesen, Howard A. Burris III, Alex A. Adjei
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma
Andrew Poklepovic, Leena Youseffian, Mary Winning, Christine A. Birdsell, Nancy A. Crosby, Viswanathan Ramakrishnan, Marc S. Ernstoff, John D. Roberts
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
Noelle K. LoConte, Kyle D. Holen, William R. Schelman, Daniel L. Mulkerin, Dustin A. Deming, Hilary R. Hernan, Anne M. Traynor, Timothy Goggins, David Groteluschen, Kurt Oettel, Emily Robinson, Sam J. Lubner
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery
Nigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, Janis Eglitis, Viktor Paramonov, Peter McCormack, Helen Swaisland, Maria Cavallin, Tony Parry, James Carmichael, J. Michael Dixon
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
F. E. Stuurman, E. E. Voest, A. Awada, P. O. Witteveen, T. Bergeland, P.-A. Hals, W. Rasch, J. H. M. Schellens, A. Hendlisz
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies
Aung Naing, Roger Cohen, Grace K. Dy, David S. Hong, Lyn Dyster, David G. Hangauer, Rudolf Kwan, Gerald Fetterly, Razelle Kurzrock, Alex A. Adjei
A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
Sunil Sharma, Joachim Beck, Monica Mita, Sofia Paul, Margaret M. Woo, Margaret Squier, Brian Gadbaw, H. Miles Prince
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart, Ramesh K. Ramanathan, Dawn Bassett, James A. Neidhart, Chung Hang J. Choi, Warren Chow, Vincent Chung, Stephen J. Forman, Edward Garmey, Jungyeon Hwang, D. Lynn Kalinoski, Marianna Koczywas, Jeffrey Longmate, Roger J. Melton, Robert Morgan, Jamie Oliver, Joanna J. Peterkin, John L. Ryan, Thomas Schluep, Timothy W. Synold, Przemyslaw Twardowski, Mark E. Davis, Yun Yen
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer
Robert Jones, Jacqueline Vuky, Tony Elliott, Graham Mead, José Angel Arranz, John Chester, Simon Chowdhury, Arkadiusz Z. Dudek, Volker Müller-Mattheis, Marc-Oliver Grimm, Jürgen E. Gschwend, Christian Wülfing, Peter Albers, Jianguo Li, Anna Osmukhina, Jeffrey Skolnik, Gary Hudes
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
Srikala S. Sridhar, Mary J. Mackenzie, Sebastien J. Hotte, Som D. Mukherjee, Ian F. Tannock, Nevin Murray, Christian Kollmannsberger, Masoom A. Haider, Eric X. Chen, Robert Halford, Lisa Wang, S. Percy Ivy, Malcolm J. Moore
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
Darren R. Feldman, Lawrence H. Einhorn, David I. Quinn, Yohann Loriot, Johnathan K. Joffe, David J. Vaughn, Aude Fléchon, Julio Hajdenberg, Abdel-Baset Halim, Hamim Zahir, Robert J. Motzer
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
Harry P. Erba, Hamid Sayar, Mark Juckett, Michael Lahn, Valerie Andre, Sophie Callies, Shelly Schmidt, Sunil Kadam, John T. Brandt, Dirk Van Bockstaele, Michael Andreeff
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study
Luca Moscetti, Fabrizio Nelli, Maria A Fabbri, Isabella Sperduti, Daniele Alesini, Enrico Cortesi, Donatello Gemma, Teresa Gamucci, Roberta Grande, Ida Pavese, Daniela Franco, Enzo M. Ruggeri
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
Robert Dreicer, Jorge Garcia, Brian Rini, Nicholas Vogelzang, Sandy Srinivas, Bradley Somer, Peipei Shi, Marek Kania, Derek Raghavan
Potential factors correlating to the PMDA’s decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan
Keitaro Nakajima, Koji Chiba, Hisao Tsubamoto, Jaimie Walsh, Laurie Strawn, Toshio Suwa
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials
Mitesh J. Borad, Arundhati D. Soman, Martin Benjamin, Daniel Casa, Waibhav D. Tembe, Barbara F. Piper, Ramesh Ramanathan, Raoul Tibes, Gayle Jameson, Karen Ansaldo, Daniel D. Von Hoff
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment
Moshe Rogosnitzky, Milton J. Finegold, Patricia J. McLaughlin, Ian S. Zagon
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kyung Won Kim, Nikhil H. Ramaiya, Katherine M. Krajewski, Jyothi P. Jagannathan, Sree Harsha Tirumani, Amitabh Srivastava, Nageatte Ibrahim
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis
Viswanath Reddy Belum, Shenhong Wu, Mario E. Lacouture
Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials
M. Slingerland, C. Cerella, H. J. Guchelaar, M. Diederich, H. Gelderblom
Erratum to: Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma
Andrew Poklepovic, Leena E. Youssefian, Mary Winning, Christine A. Birdsell, Nancy A. Crosby, Viswanathan Ramakrishnan, Marc S. Ernstoff, John D. Roberts